{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:50:44Z","timestamp":1787021444300,"version":"build-2736575974"},"reference-count":45,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2023,7,25]]},"DOI":"10.1253\/circj.cj-22-0830","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T18:12:44Z","timestamp":1678990364000},"page":"1130-1137","source":"Crossref","is-referenced-by-count":7,"title":["Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction"],"prefix":"10.1253","volume":"87","author":[{"given":"Mayumi","family":"Kase","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fujiki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kashimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Okura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Niigata Cancer Center Hospita"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Kodera","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Niigata Bandai Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Niigata Minami Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Niigata City General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Bannai","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Misono Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taturo","family":"Hatano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Kuwana Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Center, Niigata University Medical and Dental Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Clinical and Translational Research Center, Niigata University Medical and Dental Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"},{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol<\/i> 2022; 79: 1757\u20131780, doi:10.1016\/j.jacc.2021.12.011.","DOI":"10.1016\/j.jacc.2021.12.011"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2021; 42: 3599\u20133726, doi:10.1093\/eurheartj\/ehab368.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>Eur Heart J<\/i> 2016; 37: 455\u2013462, doi:10.1093\/eurheartj\/ehv464.","DOI":"10.1093\/eurheartj\/ehv464"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. <i>Circulation<\/i> 2020; 141: 352\u2013361, doi:10.1161\/circulationaha.119.044586.","DOI":"10.1161\/CIRCULATIONAHA.119.044586"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>Eur J Heart Fail<\/i> 2018; 20: 1230\u20131239, doi:10.1002\/ejhf.1149.","DOI":"10.1002\/ejhf.1149"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. <i>Eur Heart J<\/i> 2018; 39: 26\u201335, doi:10.1093\/eurheartj\/ehx564.","DOI":"10.1093\/eurheartj\/ehx564"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction: A report from the CHART-2 Study. <i>Eur J Heart Fail<\/i> 2017; 19: 1258\u20131269, doi:10.1002\/ejhf.807.","DOI":"10.1002\/ejhf.807"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. <i>J Am Coll Cardiol<\/i> 2018; 72: 351\u2013366, doi:10.1016\/j.jacc.2018.04.070.","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: Insights from the CHAMP-HF registry. <i>JACC Heart Fail<\/i> 2019; 7: 350\u2013358, doi:10.1016\/j.jchf.2018.11.011.","DOI":"10.1016\/j.jchf.2018.11.011"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Seferovi\u0107 PM, Polovina M, Adlbrecht C, B\u011blohl\u00e1vek J, Chioncel O, Goncalvesov\u00e1 E, et al. Navigating between Scylla and Charybdis: Challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. <i>Eur J Heart Fail<\/i> 2021; 23: 1999\u20132007, doi:10.1002\/ejhf.2378.","DOI":"10.1002\/ejhf.2378"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Komajda M, Sch\u00f6pe J, Wagenpfeil S, Tavazzi L, B\u00f6hm M, Ponikowski P, et al. Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: The QUALIFY international registry. <i>Eur J Heart Fail<\/i> 2019; 21: 921\u2013929, doi:10.1002\/ejhf.1459.","DOI":"10.1002\/ejhf.1459"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of medical therapy for heart failure with reduced ejection fraction. <i>J Am Coll Cardio<\/i> 2019; 73: 2365\u20132383, doi:10.1016\/j.jacc.2019.02.015.","DOI":"10.1016\/j.jacc.2019.02.015"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Fujiki S, Kashimura T, Okura Y, Kodera K, Watanabe H, Tanaka K, et al. Incidence and risk factors of future need for long-term care insurance in Japanese elderly patients with left ventricular systolic dysfunction. <i>Circ J<\/i> 2021; 86: 158\u2013165, doi:10.1253\/circj.CJ-21-0580.","DOI":"10.1253\/circj.CJ-21-0580"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kim MJ, Yabushita N, Kim MK, Nemoto M, Seino S, Tanaka K. Mobility performance tests for discriminating high risk of frailty in community-dwelling older women. <i>Arch Gerontol Geriatr<\/i> 2010; 51: 192\u2013198, doi:10.1016\/j.archger.2009.10.007.","DOI":"10.1016\/j.archger.2009.10.007"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Nemoto M, Yabushita N, Kim MJ, Matsuo T, Seino S, Tanaka K. Assessment of vulnerable older adults\u2019 physical function according to the Japanese Long-Term Care Insurance (LTCI) system and Fried\u2019s criteria for frailty syndrome. <i>Arch Gerontol Geriatr<\/i> 2012; 55: 385\u2013391, doi:10.1016\/j.archger.2011.10.004.","DOI":"10.1016\/j.archger.2011.10.004"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Tamiya N, Noguchi H, Nishi A, Reich MR, Ikegami N, Hashimoto H, et al. Population ageing and wellbeing: Lessons from Japan\u2019s long-term care insurance policy. <i>Lancet<\/i> 2011; 378: 1183\u20131192, doi:10.1016\/S0140-6736(11)61176-8.","DOI":"10.1016\/S0140-6736(11)61176-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. <i>J Chronic Dis<\/i> 1987; 40: 373\u2013383, doi:10.1016\/0021-9681(87)90171-8.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kr\u00fcck F, Bablok W, Besenfelder E, Betzien G, Kaufmann B. Clinical and pharmacological investigations of the new saluretic azosemid. <i>Eur J Clin Pharmacol<\/i> 1978; 14: 153\u2013161, doi:10.1007\/bf02089953.","DOI":"10.1007\/BF02089953"},{"key":"19","unstructured":"19. Medication Safety in Polypharmacy. Geneva: World Health Organization; 2019 (WHO\/UHC\/SDS\/2019.11). Licence: CC BY-NC-SA 3.0 IGO. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325454\/WHO-UHC-SDS-2019.11-eng.pdf?sequence=1&amp;isAllowed=y (accessed February 11, 2023)."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. <i>BMC Geriatr<\/i> 2017; 17: 230, doi:10.1186\/s12877-017-0621-2.","DOI":"10.1186\/s12877-017-0621-2"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: A systematic review. <i>Heart Fail Rev<\/i> 2022; 27: 465\u2013492, doi:10.1007\/s10741-021-10135-4.","DOI":"10.1007\/s10741-021-10135-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>Eur Heart J<\/i> 2008; 29: 2388\u20132442, doi:10.1016\/j.ejheart.2008.08.005.","DOI":"10.1016\/j.ejheart.2008.08.005"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>Eur J Heart Fail<\/i> 2016; 18: 891\u2013975, doi:10.1093\/eurheartj\/ehw128.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. <i>Bone Marrow Transplant<\/i> 2013; 48: 452\u2013458, doi:10.1038\/bmt.2012.244.","DOI":"10.1038\/bmt.2012.244"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rothschild JM, Bates DW, Leape LL. Preventable medical injuries in older patients. <i>Arch Intern Med<\/i> 2000; 160: 2717\u20132728, doi:10.1001\/archinte.160.18.2717.","DOI":"10.1001\/archinte.160.18.2717"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Oziera\u0144ski K, Balsam P, Tymi\u0144ska A, Peller M, Kap\u0142on-Cie\u015blicka A, Marchel M, et al. Heart failure in elderly patients: Differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF long-term registry. <i>Pol Arch Med Wewn<\/i> 2016; 126: 502\u2013513, doi:10.20452\/pamw.3490.","DOI":"10.20452\/pamw.3490"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GC, et al. Influence of age on the management of heart failure: Findings from Get With the Guidelines\u2013Heart Failure (GWTG-HF). <i>Am Heart J<\/i> 2009; 157: 1010\u20131017, doi:10.1016\/j.ahj.2009.03.010.","DOI":"10.1016\/j.ahj.2009.03.010"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. H\u00fclsmann M, Berger R, M\u00f6rtl D, Pacher R. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: A data-based substudy of the EuroHeart Failure Survey. <i>Eur J Heart Fail<\/i> 2005; 7: 657\u2013661, doi:10.1016\/j.ejheart.2004.11.011.","DOI":"10.1016\/j.ejheart.2004.11.011"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Lund LH, Benson L, St\u00e5hlberg M, Braunschweig F, Edner M, Dahlstr\u00f6m U, et al. Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: Findings from 14,713 patients in the Swedish Heart Failure Registry. <i>Eur J Heart Fail<\/i> 2014; 16: 1073\u20131081, doi:10.1002\/ejhf.162.","DOI":"10.1002\/ejhf.162"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Veenis JF, Brunner-La Rocca HP, Linssen GC, Geerlings PR, Van Gent MWF, Aksoy I, et al. Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. <i>Eur J Prev Cardiol<\/i> 2019; 26: 1399\u20131407, doi:10.1177\/2047487319835042.","DOI":"10.1177\/2047487319835042"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. <i>Lancet<\/i> 2012; 380: 37\u201343, doi:10.1016\/s0140-6736(12)60240-2.","DOI":"10.1016\/S0140-6736(12)60240-2"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of prevalence studies on multimorbidity: Toward a more uniform methodology. <i>Ann Fam Med<\/i> 2012; 10: 142\u2013151, doi:10.1370\/afm.1337.","DOI":"10.1370\/afm.1337"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Matsue Y, Kamiya K, Saito H, Saito K, Ogasahara Y, Maekawa E, et al. Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: The FRAGILE-HF cohort study. <i>Eur J Heart Fail<\/i> 2020; 22: 2112\u20132119, doi:10.1002\/ejhf.1926.","DOI":"10.1002\/ejhf.1926"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Khan MS, Segar MW, Usman MS, Singh S, Greene SJ, Fonarow GC, et al. Frailty, guideline-directed medical therapy, and outcomes in HFrEF: From the GUIDE-IT trial. <i>JACC Heart Fail<\/i> 2022; 10: 266\u2013275, doi:10.1016\/j.jchf.2021.12.004.","DOI":"10.1016\/j.jchf.2021.12.004"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, et al. Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: Data from the QUALIFY global survey. <i>Eur J Heart Fail<\/i> 2016; 18: 514\u2013522, doi:10.1002\/ejhf.510.","DOI":"10.1002\/ejhf.510"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CW, Sbolli M, Cani D, et al. Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: A secondary analysis of a randomized clinical trial. <i>JAMA Cardiol<\/i> 2020; 5: 757\u2013764, doi:10.1001\/jamacardio.2020.0640.","DOI":"10.1001\/jamacardio.2020.0640"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: Impact of a pharmacist in a multidisciplinary HF clinic. <i>J Card Fail<\/i> 2011; 17: 217\u2013223, doi:10.1016\/j.cardfail.2010.10.009.","DOI":"10.1016\/j.cardfail.2010.10.009"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Somberg J. Heart failure research and polypharmacy. <i>Cardiol Res<\/i> 2022; 13: 1, doi:10.14740\/cr1356.","DOI":"10.14740\/cr1356"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Fried TR, Tinetti ME, Iannone L, O\u2019Leary JR, Towle V, Van Ness PH, et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. <i>Arch Intern Med<\/i> 2011; 171: 1854\u20131856, doi:10.1001\/archinternmed.2011.424.","DOI":"10.1001\/archinternmed.2011.424"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Dunlay SM, Swetz KM, Redfield MM, Mueller PS, Roger VL. Resuscitation preferences in community patients with heart failure. <i>Circ Cardiovasc Qual Outcomes<\/i> 2014; 7: 353\u2013359, doi:10.1161\/circoutcomes.113.000759.","DOI":"10.1161\/CIRCOUTCOMES.113.000759"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. <i>Circulation<\/i> 2005; 112: 2426\u20132435, doi:10.1161\/CIRCULATIONAHA.105.582320.","DOI":"10.1161\/CIRCULATIONAHA.105.582320"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. SOLVD Investigators; Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. <i>N Engl J Med<\/i> 1991; 325: 293\u2013302, doi:10.1056\/NEJM199108013250501.","DOI":"10.1056\/NEJM199108013250501"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. <i>Lancet<\/i> 2003; 362: 772\u2013776, doi:10.1016\/S0140-6736(03)14284-5.","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med<\/i> 1999; 341: 709\u2013717, doi:10.1056\/NEJM199909023411001.","DOI":"10.1056\/NEJM199909023411001"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Takahashi S, Yonekura Y, Takanashi N, Tanno K. Risk Factors of long-term care insurance certification in Japan: A scoping review. <i>Int J Environ Res Public Health<\/i> 2022; 19: 2162, doi:10.3390\/ijerph19042162.","DOI":"10.3390\/ijerph19042162"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/87\/8\/87_CJ-22-0830\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:40:24Z","timestamp":1715560824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/87\/8\/87_CJ-22-0830\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-22-0830","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"article-number":"CJ-22-0830"}}